Sarcoma  >>  selurampanel (BGG492)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
selurampanel (BGG492) / Novartis
NCT02150213 / 2013-003431-29: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Completed
2
59
US, Europe, RoW
MRI, CT or ultrasound was permitted if MRI was contraindicated, Magnetic Resonance Imaging Computed tomography, Dexamethasone Supression Test, Sonogram, Sonogram ultrasound, Biopsy, Uterine Biopsy, BGG492, Selurampanel
Novartis Pharmaceuticals
Adrenocortical Adenoma, Endometrial Stromal Sarcomas
09/15
09/15

Download Options